Le Lézard
Classified in: Health
Subject: AVO

To End the Opioid Crisis, AACC Emphasizes That Clinical Laboratories, Healthcare Providers, and Federal Agencies Must Work Together

ANAHEIM, Calif., Aug. 4, 2019 /PRNewswire/ -- AACC released a position statement today calling for increased collaboration between clinical laboratories, the healthcare community, and federal agencies to end the opioid epidemic. The statement emphasizes that labs are critical to preventing opioid abuse and urges the medical community and government to leverage the expertise of clinical laboratory professionals to curb soaring drug overdoses in the U.S.


From 2016 to 2017, fatal overdoses caused by synthetic opioids jumped by 46%, a surge that contributed heavily to the more than 70,000 drug overdose-related deaths in 2017. Synthetic opioids are so deadly because of their extreme potency, but also because common tests often can't detect them. This makes it difficult to determine whether synthetic opioids are the cause of a drug overdose and to detect when a patient is abusing synthetic opioids. Laboratories with the appropriate experts and the right instrumentation and tests can identify many synthetic opioids that would otherwise be missed. Without this information, patients might not get crucial addiction or overdose treatment. Clinicians especially need to know if an overdose is due to a long-lasting synthetic opioid, because in these cases patients may need additional doses of the opioid antidote naloxone to prevent a relapse of overdose symptoms. Public health officials also need to know which specific drugs people are using in their locales in order to predict overdose outbreaks and rapidly coordinate preventive efforts.

To improve the nationwide response to synthetic opioids, AACC urges clinical care teams to include laboratory experts, and encourages Congress and federal agencies to enhance labs' ability to identify new drug use trends. Laboratory experts have extensive knowledge about the appropriate use and limitations of drug tests, and can provide guidance to clinical care teams on test ordering and result interpretation so that addiction and overdose patients get the best treatment. Lab experts have also developed sophisticated tests that detect the newest synthetic opioids. AACC recommends that the Food and Drug Administration expedite regulatory approval for these tests so that all healthcare facilities can use them.

Additionally, the association calls on Congress to fund an increase in the number of laboratories that identify synthetic drugs at the state and local level. Congress should also fund the development of partnerships that rapidly share synthetic opioid data between forensic, public health, and clinical labs, and relevant government agencies. This will ensure that strategies to combat opioid abuse are based on the most timely, comprehensive data possible.

"Clinical laboratories are often the first to identify synthetic opioids used on the streets and can provide much-needed expertise about the wide range of chemicals in these drugs and the frequency of their use in local communities," said AACC CEO Janet B. Kreizman. "If healthcare providers and the government work closely with lab experts as AACC recommends, overdose victims and patients with addiction problems will get the vital care they need."

About AACC
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.

Christine DeLong
Senior Manager, Communications & PR
(p) 202.835.8722

Molly Polen
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472


These press releases may also interest you

at 20:12
The food recall warning issued on August 1, 2020 has been updated to include additional distribution information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Industry is...

at 19:16
Today, the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative...

at 19:15
The "Syringe and Needle Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global syringe and needle market is expected to grow at a CAGR of over 10% during the period 2019-2025 The global...

at 19:00
The "US Acne & Rosacea Market: Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering. The US acne market is expected to reach US$4.49 billion in 2024, recording growth at a CAGR of 4.12% during the period...

at 18:15
The "Coronavirus Disease 2019 (COVID-19) - Analysis of the Emerging Disease Landscape - June 2020" report has been added to ResearchAndMarkets.com's offering. The Epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to...

at 18:10
Service Corporation International (the "Company") announces that the previously announced cash tender offer for any and all of its 5.375% Senior Notes due 2024 (CUSIP No. 817565 CB8/ ISIN No. US817565CB82) (the "Notes"), which expired today at 5:00...

News published on 4 august 2019 at 20:00 and distributed by: